RSRTRNA editing specialist ProQR Therapeutics NV has deepened its collaboration with the Rett Syndrome Research Trust, which extented its funding of the preclinical MECP2 inhibitor AX-2402 to US$9.1m to speed up the translation to clinical trials.
ADVERTISEMENT